Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

被引：22

作者：

Guan, Wei-jie ^{[1
,2
]}

Liang, Wen-hua ^{[2
,3
]}

Zhao, Yi ^{[2
,3
]}

Liang, Heng-rui ^{[2
,3
]}

Chen, Zi-sheng ^{[2
,3
,4
]}

Li, Yi-min ^{[2
,5
]}

Liu, Xiao-qing ^{[2
,5
]}

Chen, Ru-chong ^{[1
,2
]}

Tang, Chun-li ^{[1
,2
]}

Wang, Tao ^{[1
,2
]}

Ou, Chun-quan ^{[6
]}

Li, Li ^{[6
]}

Chen, Ping-yan ^{[6
]}

Sang, Ling ^{[2
,5
]}

Wang, Wei ^{[2
,3
]}

Li, Jian-fu ^{[2
,3
]}

Li, Cai-chen ^{[2
,3
]}

Ou, Li-min ^{[2
,3
]}

Cheng, Bo ^{[2
,3
]}

Xiong, Shan ^{[2
,3
]}

Ni, Zheng-yi ^{[7
]}

Xiang, Jie ^{[7
]}

Hu, Yu ^{[8
]}

Liu, Lei ^{[9
,10
]}

Shan, Hong ^{[11
]}

Lei, Chun-liang ^{[12
]}

Peng, Yi-xiang ^{[13
]}

Wei, Li ^{[14
]}

Liu, Yong ^{[15
]}

Hu, Ya-hua ^{[16
]}

Peng, Peng ^{[17
]}

Wang, Jian-ming ^{[18
]}

Liu, Ji-yang ^{[19
]}

Chen, Zhong ^{[20
]}

Li, Gang ^{[21
]}

Zheng, Zhi-jian ^{[22
]}

Qiu, Shao-qin ^{[23
]}

Luo, Jie ^{[24
]}

Ye, Chang-jiang ^{[25
]}

Zhu, Shao-yong ^{[26
]}

Cheng, Lin-ling ^{[1
,2
]}

Ye, Feng ^{[1
,2
]}

Li, Shi-yue ^{[1
,2
]}

Zheng, Jin-ping ^{[1
,2
]}

Zhang, Nuo-fu ^{[1
,2
]}

Zhong, Nan-shan ^{[1
,2
]}

He, Jian-xing ^{[2
,3
]}

机构：

[1] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Peoples R China

[2] Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China

[3] Guangzhou Med Univ, China State Key Lab Resp Dis, Dept Thorac Oncol & Surg, Guangzhou, Peoples R China

[4] Guangzhou Med Univ, Affiliated Hosp 6, Qingyuan, Peoples R China

[5] Guangzhou Med Univ, Affiliated Hosp 1, China State Key Lab Resp Dis, Dept Pulm & Crit Care Med, Guangzhou, Peoples R China

[6] Southern Med Univ, Guangdong Prov Key Lab Trop Dis Res, State Key Lab Organ Failure Res, Dept Biostat,Sch Publ Hlth, Guangzhou, Peoples R China

[7] Wuhan Jin Yintan Hosp, Wuhan, Peoples R China

[8] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China

[9] Shenzhen Third Peoples Hosp, Shenzhen, Peoples R China

[10] Southern Univ Sci & Technol, Natl Clin Res Ctr Infect Dis, Affiliated Hosp 2, Shenzhen, Peoples R China

[11] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China

[12] Guangzhou Med Univ, Guangzhou Eighth Peoples Hosp, Guangzhou, Peoples R China

[13] Cent Hosp Wuhan, Wuhan, Peoples R China

[14] Wuhan Hosp Tradit Chinese & Western Med, Wuhan Hosp 1, Wuhan, Peoples R China

[15] Chengdu Publ Hlth Clin Med Ctr, Chengdu, Peoples R China

[16] Hubei Polytech Univ, Affiliated Hosp, Huangshi Cent Hosp, Edong Healthcare Grp, Huangshi, Hubei, Peoples R China

[17] Wuhan Pulm Hosp, Wuhan, Peoples R China

[18] Wuhan Univ Sci & Technol, Tianyou Hosp, Wuhan, Peoples R China

[19] First Hosp Changsha, Changsha, Peoples R China

[20] Third Peoples Hosp Hainan Prov, Sanya, Peoples R China

[21] Huanggang Cent Hosp, Huanggang, Peoples R China

[22] Wenling First Peoples Hosp, Wenling, Peoples R China

[23] Third Peoples Hosp Yichang, Yichang, Peoples R China

[24] Hubei Univ Med, Affiliated Taihe Hosp, Shiyan, Peoples R China

[25] Xiantao First Peoples Hosp, Xiantao, Peoples R China

[26] Peoples Hosp Huangpi Dist, Wuhan, Peoples R China

来源：

EUROPEAN RESPIRATORY JOURNAL | 2020年 / 55卷 / 05期

关键词：

RESPIRATORY SYNDROME CORONAVIRUS; DIABETES-MELLITUS; MERS-COV; HYPERTENSION; INFECTION; OUTCOMES; DEATH; RISK; SARS;

D O I：

10.1183/13993003.00547-2020

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background: The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide. Objective: To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status. Methods: We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities. Results: The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424-5.048)), diabetes (1.59 (1.032.45)), hypertension (1.58 (1.07-2.32)) and malignancy (3.50 (1.60-7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16-2.77) among patients with at least one comorbidity and 2.59 (1.61 4.17) among patients with two or more comorbidities. Conclusion: Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.

引用

页数：14

共 50 条

[41] Sociodemographic trends in COVID-19 mortality in patients with cancer: A nationwide analysis.
Jambunathan, Sree
Lang, Jacob
Mays, Malik
Hadziahmetovic, Mersiha
Oke, Oluchi Ukaegbu
Ekwenna, Obi
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42] Outcomes of COVID-19 In-Patients With Inflammatory Bowel Disease: A Nationwide Analysis
Aldiabat, Mohammad
Butt, Muhammad Ali
Daniel, Tyrell
Jagdish, Balaji
Rock, James, III
Sudan, Aarushi
Al-Ahmad, Majd
Altarawneh, Saba
Alsakarneh, Saqr
Jabri, Ahmad
Alhuneafat, Laith
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S723 - S723
[43] Outcomes of COVID-19 hospitalizations in patients with sickle cell disease: A nationwide analysis
Ilerhunmwuwa, Nosakhare Paul
Inyang, Lawrence
Hakobyan, Narek
Wasifuddin, Mustafa
Tahir, Muhammad
Aiwuyo, Henry
Ankah, Paul
Torere, Beatrice E.
Amaechi, Uchenna M.
Wang, Jen Chin
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (03) : 432 - 440
[44] Outcomes of intensive care unit patients with COVID-19: a nationwide analysis in Russia
Moiseev, S.
Avdeev, S.
Brovko, M.
Bulanov, N.
Tao, E.
Fomin, V.
[J]. ANAESTHESIA, 2021, 76 : 11 - 12
[45] Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China
Zou, Ying
Guo, Hongying
Zhang, Yuyi
Zhang, Zhengguo
Liu, Yu
Wang, Jiefei
Lu, Hongzhou
Qian, Zhiping
[J]. BIOSCIENCE TRENDS, 2020, 14 (04) : 285 - 289
[46] COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity
Lundstrom, Kenneth
Hromic-Jahjefendic, Altijana
Bilajac, Esma
Aljabali, Alaa A. A.
Baralic, Katarina
Sabri, Nagwa A.
Shehata, Eslam M.
Raslan, Mohamed
Ferreira, Ana Claudia B. H.
Orlandi, Lidiane
Serrano-Aroca, Angel
Tambuwala, Murtaza M.
Uversky, Vladimir N.
Azevedo, Vasco
Alzahrani, Khalid J.
Alsharifm, Khalaf F.
Halawani, Ibrahim F.
Alzahrani, Fuad M.
Redwan, Elrashdy M.
Barhl, Debmalya
[J]. CELLULAR SIGNALLING, 2023, 101
[47] The Experience of Patients with COVID-19 in China: An Interpretative Phenomenological Analysis
Wang, Yanbo
Pan, Xiao
Bai, Yonghai
[J]. PSYCHOLOGY RESEARCH AND BEHAVIOR MANAGEMENT, 2021, 14 : 877 - 887
[48] Autopsy of COVID-19 patients in China
Xiu-Wu Bian
the COVID-19 Pathology Team
[J]. National Science Review, 2020, 7 (09) : 1414 - 1418
[49] Impact of the COVID-19 Outbreak on Orthopedic Surgery: A Nationwide Analysis of the First Pandemic Year
Barahona, Maximiliano
Infante, Carlos A.
Palet, Miguel J.
Barahona, Macarena A.
Barrientos, Cristian
Martinez, Alvaro
[J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (08)
[50] Autopsy of COVID-19 patients in China
Bian, Xiu-Wu
[J]. NATIONAL SCIENCE REVIEW, 2020, 7 (09) : 1414 - 1418

← 1 2 3 4 5 →